TD Asset Management
TARS icon

TD Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

TD Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
22,024
-7,988
-27% -$510K ﹤0.01% 1037
2026
Q1 		$2.11M Sell
30,012
-34,000
-53% -$2.38M ﹤0.01% 954
2025
Q4 		$5.24M Buy
64,012
+11,320
+21% +$845K ﹤0.01% 794
2025
Q3 		$3.13M Buy
52,692
+9,400
+22% +$463K ﹤0.01% 877
2025
Q2 		$1.75M Sell
43,292
-9,200
-18% -$414K ﹤0.01% 969
2025
Q1 		$2.7M Sell
52,492
-2,496
-5% -$123K ﹤0.01% 891
2024
Q4 		$3.04M Buy
54,988
+25,200
+85% +$1.14M ﹤0.01% 890
2024
Q3 		$968K Sell
29,788
-5,600
-16% -$157K ﹤0.01% 1190
2024
Q2 		$962K Sell
35,388
-13,200
-27% -$444K ﹤0.01% 1168
2024
Q1 		$1.77M Buy
+48,588
New +$1.43M ﹤0.01% 1060

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TD Asset Management's TARS Position: Q2 2026 in Review

TD Asset Management reduced its Tarsus Pharmaceuticals (TARS) stake by 27% in Q2 2026, selling an estimated $510K and leaving 22,024 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

TD Asset Management first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.24M in Q4 2025. 165 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • TD Asset Management held 22,024 shares of Tarsus Pharmaceuticals worth $1.39M as of Q2 2026.
  • TD Asset Management sold 7,988 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $510K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1037 holding.
  • TD Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • TD Asset Management's Tarsus Pharmaceuticals position peaked at $5.24M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.